Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
| ▸ | PYGL | P06737 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479851 | 1.00 | CA2 (0.40) | CA2CA1CA7CNR2MEN1 | |
| SCHEMBL192054 | 1.00 | CA2 (0.40) | CA2CA1CA7CNR2MEN1 | |
| SCHEMBL193767 | 0.84 | MEN1 (0.31) | MEN1GAAKMT2ATGFBR1 | |
| SCHEMBL193766 | 0.84 | MEN1 (0.31) | MEN1GAAKMT2ATGFBR1 | |
| SCHEMBL204757 | 0.83 | MEN1 (0.33) | MEN1GAAKMT2A | |
| SCHEMBL15898007 | 0.83 | GAA (0.33) | MEN1GAAKMT2A | |
| SCHEMBL1985522 | 0.83 | MEN1 (0.33) | MEN1GAAKMT2A | |
| SCHEMBL90052 | 0.83 | CA2 (0.50) | CA2CA1CA7MEN1GAA | |
| SCHEMBL57432 | 0.83 | CA2 (0.50) | CA2CA1CA7MEN1GAA | |
| SCHEMBL83699 | 0.83 | CA2 (0.50) | CA2CA1CA7MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215792-A | Method for preparing atazanavir or sulfate thereof | 江西富祥药业股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-114890916-A | Preparation method of N-methoxycarbonyl-L-tert-leucine | 常州吉恩药业有限公司 | 2022-08-12 | — | — | CN | claimed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | claimed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | claimed |
| US-20150183742-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR BISULFATE | LAURUS LABS LIMITED (IN) | 2015-07-02 | — | — | US | claimed |
| EP-2888230-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ATAZANAVIR BISULFATE | Laurus Labs Private Limited (IN) | 2015-07-01 | — | — | EP | claimed |
| US-20140343290-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | RANBAXY LABORATORIES LIMITED (IN) | 2014-11-20 | — | — | US | claimed |
| WO-2014030173-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ATAZANAVIR BISULFATE | LAURUS LABS PRIVATE LIMITED (IN) | 2014-02-27 | — | — | WO | claimed |
| WO-2013014633-A1 | PROCESS FOR PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | RANBAXY LABORATORIES LIMITED (IN) | 2013-01-31 | — | — | WO | claimed |
| US-20110178305-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-21 | — | — | US | claimed |
| EP-2288593-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | Ranbaxy Laboratories Limited (IN) | 2011-03-02 | — | — | EP | claimed |
| WO-2009136365-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2009-11-12 | — | — | WO | claimed |
| EP-1930324-A1 | Process for the preparation of atazanavir | SOLMAG S.p.A. (IT) | 2008-06-11 | — | — | EP | claimed |
| EP-4649086-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250223259-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025037206-A1 | DEUTERATED ANTIVIRAL COMPOUNDS | PFIZER INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-1998003476-A1 | ANILINOPEPTIDE DERIVATIVES | NOVARTIS AG (CH) | 1998-01-29 | — | — | WO | disclosed |
| WO-1997046514-A1 | PROCESS FOR THE PREPARATION OF HYDRAZINE DERIVATIVES USEFUL AS INTERMEDIATES FOR THE PREPARATION OF PEPTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997019055-A1 | AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES | NOVARTIS AG (CH) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178305-A1 | PROCESS FOR THE PREPARATION OF 3,4-EPOXY-2-AMINO-1-SUBSTITUTED BUTANE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | CYP2S1, TYMS, TBXAS1 | CA2 2635/4885CA1 3327/4885CA7 3133/4885 |
| US-20250223259-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | ACE2, PRSS2, PRSS1 | CA2 743/4885CA1 1503/4885CA7 2076/4885 |
| US-20140343290-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | DNPEP, NSUN2, JMJD7 | CA2 1515/4885CA1 1369/4885CA7 763/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CA2 4674/4885CA1 4852/4885CA7 4349/4885 |
| US-20150183742-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR BISULFATE | SAMHD1, CYP3A4, APOBEC3C | CA2 4084/4885CA1 4415/4885CA7 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.